Macrocure Ltd Company Profile (NASDAQ:MCUR)

About Macrocure Ltd (NASDAQ:MCUR)

Macrocure Ltd logoLeap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MCUR
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $1.51
  • 200 Day Moving Avg: $1.54
  • 52 Week Range: $0.75 - $3.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.72
  • P/E Growth: 0.00
  • Return on Equity: -24.50%
  • Return on Assets: -22.85%
  • Current Ratio: 44.95%
  • Average Volume: 40,588 shs.
  • Beta: 0.62

Frequently Asked Questions for Macrocure Ltd (NASDAQ:MCUR)

What is Macrocure Ltd's stock symbol?

Macrocure Ltd trades on the NASDAQ under the ticker symbol "MCUR."

How were Macrocure Ltd's earnings last quarter?

Macrocure Ltd (NASDAQ:MCUR) announced its earnings results on Tuesday, November, 17th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. View Macrocure Ltd's Earnings History.

Who are some of Macrocure Ltd's key competitors?

How do I buy Macrocure Ltd stock?

Shares of Macrocure Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Macrocure Ltd's stock price today?

One share of Macrocure Ltd stock can currently be purchased for approximately $1.51.

MarketBeat Community Rating for Macrocure Ltd (NASDAQ MCUR)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  116
MarketBeat's community ratings are surveys of what our community members think about Macrocure Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Macrocure Ltd (NASDAQ:MCUR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Macrocure Ltd (NASDAQ:MCUR)
Price Target History for Macrocure Ltd (NASDAQ:MCUR)
Analysts' Ratings History for Macrocure Ltd (NASDAQ:MCUR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2016Credit Suisse GroupDowngradeNeutral -> Underperform$1.00N/AView Rating Details
10/28/2015Jefferies Group LLCLower Price TargetHold$1.50N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Macrocure Ltd (NASDAQ:MCUR)
Earnings by Quarter for Macrocure Ltd (NASDAQ:MCUR)
Earnings History by Quarter for Macrocure Ltd (NASDAQ MCUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2015Q3($0.36)($0.32)ViewN/AView Earnings Details
8/4/2015Q215($0.37)($0.37)ViewListenView Earnings Details
5/11/2015Q115($0.38)($0.38)$0.01 millionViewN/AView Earnings Details
3/17/2015Q414($0.28)($0.42)ViewN/AView Earnings Details
11/3/2014Q314($0.31)($0.70)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Macrocure Ltd (NASDAQ:MCUR)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS


Dividend History for Macrocure Ltd (NASDAQ:MCUR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Macrocure Ltd (NASDAQ:MCUR)
No insider trades for this company have been tracked by


Headline Trends for Macrocure Ltd (NASDAQ:MCUR)
Latest Headlines for Macrocure Ltd (NASDAQ:MCUR)
DateHeadline logoHead to Head Comparison: Macrocure (MCUR) and Its Peers - October 17 at 10:24 PM logoAnalyzing Macrocure (MCUR) & Its Rivals - October 8 at 4:34 AM logoAnalyzing Macrocure (MCUR) and AbbVie (ABBV) - September 29 at 12:32 PM logoContrasting Macrocure (MCUR) and Its Peers - September 24 at 6:18 PM logoMacrocure (MCUR) vs. The Competition Head to Head Analysis - September 23 at 8:32 AM logoHead to Head Contrast: Macrocure (MCUR) and Supernus Pharmaceuticals (SUPN) - August 20 at 2:06 AM logoSupernus Pharmaceuticals (SUPN) & Macrocure (MCUR) Head-To-Head Contrast - August 17 at 10:28 PM logoComparing Macrocure (MCUR) & Mallinckrodt PLC (MNK) - August 7 at 8:54 AM logoMacrocure (NASDAQ:MCUR) and Aimmune Therapeutics (AIMT) Head to Head Survey - July 24 at 9:25 AM logoMacrocure (NASDAQ:MCUR) & Mallinckrodt PLC (MNK) Head-To-Head Survey - July 20 at 8:56 AM logoAnalyzing Assembly Biosciences (ASMB) & Macrocure (MCUR) - July 5 at 8:05 AM logoMacrocure (MCUR) Completes Merger with Leap Therapeutics - January 23 at 11:46 PM logoMacrocure (MCUR) Completes Merger with Leap Therapeutics - - January 23 at 6:44 PM logoMacrocure and Leap Therapeutics Complete Merger - January 23 at 10:15 AM logoLeap Presents Biomarker Data from Study of DKN-01 Combo with Paclitaxel in Esophageal Cancer (MCUR) - - January 20 at 1:28 AM logoLeap Therapeutics Presents Biomarker Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer - January 19 at 8:28 PM logo3:33 pm Macrocure: Leap Therapeutics reported updated clinical and biomarker data from an ongoing study of DKN-01 in patients with cancer of the esophagus and gastroesophageal junction - January 19 at 8:28 PM logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of The Board of Directors of ... - PR Newswire (press release) - December 1 at 6:26 PM logoLeap Therapeutics Presents Data from Phase 1 Study of GITR Agonist - November 12 at 6:12 PM



Macrocure Ltd (MCUR) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.